The weight-loss frenzy is making some pharma stocks much more volatile. Will the drama continue?
The recent volatility in key GLP-1 stocks has put the spotlight on the anxiety Wall Street has about the weight loss market. The market is huge — a potential $150 billion a year by the end of the ...
Lost and found: Life after Ozempic and other weight-loss drugs was just the start for these four people
Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage ...
5 new weight-loss drugs to watch in the fight for the next Ozempic
Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...
theregreview21h
Regulating Weight-Loss Drugs and Supplements
Scholars discuss the regulatory landscape surrounding GLP-1 drugs and dietary supplements.